US5980551A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition and method for making a biodegradable drug delivery stent
Assignee: Endovasc Ltd Inc
•
Filing: 1997-02-07
•
Granted: 1999-11-09
•
Expires: 2017-02-07
Abstract
Abstract A stent or vascular graft for supporting a blood vessel or organ lumen is coated with a biodegradable, resorbable and hemocompatible surface substrate. Biologically active microspheres which controllably release the biologically active agent into the vessel wall or organ to inhibit restenosis of the stent is embedded in the stent substrate. The biologically active microspheres include encapsulated PGE1 in a water soluble polyethylene glycol mix, which over a period of time dissolves and releases the PGE1 into the vessel wall or organ.
Inventors
- 👤 David P. Summers
- 👤 Jackie R. See
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:58
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; A61F2/86; A61F2/88; A61F2/885; A61L; A61L31/00; A61L31/08; A61L31/10; A61L31/14; A61L31/16; A61F2/0077; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61F2002/072; A61L2300/00; A61L2300/20; A61L2300/22; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/606; A61L2300/62; A61L2300/622; A61L2300/626; A61M; A61M25/00; A61M25/0043; A61M2025/0057
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
75 words
A stent for supporting a blood vessel, comprising: (a) a stent body; (b) a biodegradable, porous stent substrate swelled in 40% trifluoacetic acid with polyethylene oxide applied on said stent body, wherein the pores of said stent substrate are opened upon swelling said stent substrate; and (c) a polymer mixture coating said stent substrate, said polymer mixture including biologically active microspheres, and wherein said polymer mixture fills and collapes the pores of said stent substrate.
Claim 2
Dependent Claim
75 words
A stent for supporting a blood vessel, comprising: (a) a stent body; (b) a biodegradable, porous stent substrate swelled in 40% trifluoacetic acid with polyethylene oxide applied on said stent body, wherein the pores of said stent substrate are opened upon swelling said stent substrate; and (c) a polymer mixture coating said stent substrate, said polymer mixture including biologically active microspheres, and wherein said polymer mixture fills and collapes the pores of said stent substrate.
Claim 3
Dependent Claim
22 words
The stent of claim 1 wherein said substrate comprises one or more layers of a resorbable PLLA/PLC mixture encapsulating said stent body.
Claim 4
Dependent Claim
25 words
The stent of claim 2 wherein said water soluble polymer mixture comprises a slurry of polyethylene glycol (PEG) and liposomes carrying a biologically active agent.
Claim 5
Dependent Claim
53 words
The stent of claim 1 wherein said stent substrate comprises a Poly-L-lactic acid/Polycaprolactone mixture encapsulating said stent body, and wherein said polymer mixture comprises a Polyethylene glycol/lyophilized liposome surface coating on said stent body, and wherein the liposomes in said surface coating range in average diameter from about 100 nm to 200 nm.
Claim 6
Dependent Claim
32 words
The stent of claim 2 wherein said stent substrate and said polymer mixture are water soluble and resorbable, providing a continuous and gradual release of prostaglandin encapsulated in said biologically active microspheres.
Claim 7
Dependent Claim
35 words
The stent of claim 1 wherein the pores of said stent substrate define an irregular pore surface for releaseably retaining said biologically active microspheres, and wherein said microspheres contain prostaglandin E1 encapsulated in said microspheres.
Claim 8
Dependent Claim
33 words
The stent of claim 6 wherein the pores of said stent substrate have a mean pore size of 150 nm to 200 nm long axis and 50 nm to 75 nm short axis.
Claim 9
Dependent Claim
20 words
The stent of claim 7 wherein said microspheres release prostaglandin E1 at a controlled rate for up to six months.
Claim 10
Dependent Claim
16 words
The stent of claim 1 wherein said stent substrate has a porosity of 18% to 45%.
Claim 11
Independent Claim
105 words
A method of modifying cellular response in a blood vessel or organ to a disease, injury or foreign body, comprising the steps of: a) forming a water soluble and resorbable hemocompatible stent coating; b) swelling said stent coating in 40% trifluoacetic acid with polyethylene oxide to open the pores of said stent coating; c) embedding microspheres having a biologically active agent encapsuled in said microspheres in said stent coating; d) applying said stent coating on a stent body; e) positioning said stent body in the blood vessel or organ; and f) controllably releasing said biologically active agent into the blood vessel wall or target organ.
Claim 12
Independent Claim
105 words
A method of modifying cellular response in a blood vessel or organ to a disease, injury or foreign body, comprising the steps of: a) forming a water soluble and resorbable hemocompatible stent coating; b) swelling said stent coating in 40% trifluoacetic acid with polyethylene oxide to open the pores of said stent coating; c) embedding microspheres having a biologically active agent encapsuled in said microspheres in said stent coating; d) applying said stent coating on a stent body; e) positioning said stent body in the blood vessel or organ; and f) controllably releasing said biologically active agent into the blood vessel wall or target organ.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-11-08 | 2003-05-10 | 2003-11-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-11-08 | 2007-05-10 | 2007-11-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-11-08 | 2011-05-10 | 2011-11-09 | $7700.00 | Window Closed / Lapsed |